PolyPeptide Group AGXSWX:PPGN +2.07%73 Days Payable is 75.24 as of Dec. 2025, which is 27% above its 10-year median of 59.26. GuruFocus rates XSWX:PPGN with a GF Score™ of 73/100 and a GF Value™ of CHF30.82 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 922 Drug Manufacturers companies, PolyPeptide Group AG ranks worse than 56.72% on this metric.
The historical rank and industry rank for PolyPeptide Group AG's Days Payable or its related term are showing as below:
XSWX:PPGN'
s Days Payable Range Over the Past 10 Years
Min: 42.6 Med: 59.26 Max: 82.8
Current: 80.26
During the past 8 years, PolyPeptide Group AG's highest Days Payable was 82.80. The lowest was 42.60. And the median was 59.26.
XSWX:PPGN's Days Payable is ranked worse than 56.72% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs XSWX:PPGN: 80.26
PolyPeptide Group AG's Days Payable
increased
from Dec. 2024 (60.84) to Dec. 2025 (75.24).
It may suggest that PolyPeptide Group AGdelayed paying its suppliers.
PolyPeptide Group AG Days Payable Related Terms
PolyPeptide Group AG Days Payable Historical Data
* Premium members only.
The historical data trend for PolyPeptide Group AG's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:PPGN vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PolyPeptide Group AG's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PolyPeptide Group AG Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PolyPeptide Group AG's Days Payable distribution charts can be found below:
* The bar in red indicates where PolyPeptide Group AG's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
PolyPeptide Group AG's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PolyPeptide Group AG (XSWX:PPGN) has a Days Payable of 75.24 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on PolyPeptide Group AG and its competitors. This is 27% above median its historical median of 59.26. Over the past decade, PolyPeptide Group AG's Days Payable has ranged from 42.60 to 82.80. According to the industry distribution chart, PolyPeptide Group AG ranks #523 out of 922 companies in the Drug Manufacturers industry, placing it in the top 56.7%.
Is PolyPeptide Group AG's Days Payable too high?
PolyPeptide Group AG's current Days Payable of 75.24 is 27% above median its 10-year median of 59.26. Over the past 10 years, this metric has ranged from a low of 42.60 to a high of 82.80. The Drug Manufacturers industry median Days Payable is 90.84. PolyPeptide Group AG's value of 75.24 is 17.2% below this industry median. Based on the distribution chart, PolyPeptide Group AG ranks #523 out of 922 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, PolyPeptide Group AG has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PolyPeptide Group AG's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PolyPeptide Group AG ranks #523 out of 922 companies for Days Payable. This places PolyPeptide Group AG in the lower half of its industry. The industry median Days Payable is 90.84. PolyPeptide Group AG's value of 75.24 is 17.2% below this benchmark. Historically, PolyPeptide Group AG's own Days Payable has ranged from 42.60 to 82.80 over the past decade. While the company's 10-year median is 59.26 vs. the industry median of 90.84, PolyPeptide Group AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PolyPeptide Group AG's current Days Payable of 75.24 is 17.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on PolyPeptide Group AG and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PolyPeptide Group AG's current Days Payable is 75.24, which is 27% above median its own 10-year median of 59.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPeptide Group AG stock overvalued right now?
Based on GuruFocus' analysis, PolyPeptide Group AG (XSWX:PPGN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF30.82, compared to a current price of CHF49.40 — trading 60.3% above its estimated fair value. The current Days Payable is 75.24, which is 27% above median its 10-year median of 59.26 and 17.2% below the Drug Manufacturers industry median of 90.84. PolyPeptide Group AG's overall GF Score™ is 73/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For PolyPeptide Group AG (XSWX:PPGN), the current Days Payable is 75.24 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PolyPeptide Group AG (XSWX:PPGN) Overvalued in 2026?
Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued.
The current stock price of CHF49.40 is trading 60.3% above its estimated GF Value™ of CHF30.82.
GuruFocus considers PolyPeptide Group AG to be Significantly Overvalued.
Key valuation signals for XSWX:PPGN:
Days Payable: 75.24 (27% above median its 10-year median of 59.26)
GF Value™: CHF30.82 vs. price of CHF49.40 (60.3% above fair value)
Industry Position: 17.2% below the Drug Manufacturers median (#523 of 922)
No single metric tells the full story. See the XSWX:PPGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
73GF Score
Get the complete analysis for XSWX:PPGN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:PPGN has been successfully added to your 
